Scopolamine Transdermal System shortage
Scopolamine Transdermal System is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Sep 15, 2026.
Padagis is permanently stopping its scopolamine motion-sickness patch, and no supply from that maker is available now. Transderm Scop (scopolamine) 1 mg patches are still listed by other manufacturers that have not reported a shortage.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Scopolamine Transdermal System. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Nov 3, 2025Currently in shortage1 of 1 product affected.
-
Nov 3, 2025First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Padagis US LLC 📞 866-634-9120 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Scopolamine, Transdermal System, 1 mg (NDC 45802-580-46) | — | — | Discontinuation of the manufacture of the drug | — |
These rows are manufacturer reports to the FDA for Scopolamine Transdermal System — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Scopolamine Transdermal System? options further down this page.
Why is Scopolamine Transdermal System in shortage?
Padagis US LLC has reported to the FDA that they are permanently stopping the manufacture of their scopolamine 1 mg transdermal patch (the patch you wear behind your ear). This is a discontinuation, meaning this specific product from this manufacturer won't be coming back.
It's worth knowing that this report only covers Padagis US LLC and their version of the patch. Padagis did not share a specific public reason for why they made this decision — just that they are discontinuing production. Other manufacturers of scopolamine patches may have their own separate listings on this page.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Scopolamine Transdermal System, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Scopolamine Transdermal System?
The scopolamine transdermal system (the motion-sickness patch) is currently on the FDA shortage list. I want to explain what that means for you so you can plan ahead calmly.
This shortage record covers the 1 mg patch, and that strength has no available source from the manufacturer that filed this report. The reason given is that the maker, Padagis US LLC, is discontinuing production of this product. Because this is a discontinuation rather than a temporary delay, the supply problem from this manufacturer may be permanent.
Importantly, this report reflects only one manufacturer. Other companies still make the same scopolamine patch, so your pharmacy may be able to find it from a different maker.
Here is what I suggest:
- Do not stop, skip, or change how you use your patch on your own.
- Ask your pharmacy to check their wholesalers and other manufacturers — the same medicine is listed as still on the market from makers such as Mylan, Baxter (Transderm Scop), Rhodes, Amneal, Zydus, and others. It may not be in local stock, but your pharmacy can try to source it.
- If your patch cannot be found, ask your prescriber or pharmacist about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.
This is general, national information and may not match your local pharmacy's actual stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Scopolamine Transdermal System?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Scopolamine Transdermal System is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Scopolamine | SCOPOLAMINE 1 mg/3d | Patch · Transdermal | Mylan Pharmaceuticals Inc. | 00378-6470-44 |
| Transderm Scop | SCOPOLAMINE 1 mg/3d | Patch, Extended Release · Transdermal | Baxter Healthcare Corporation | 10019-0008-01 |
| Scopolamine | SCOPOLAMINE 1 mg/3d | Patch, Extended Release · Transdermal | Rhodes Pharmaceuticals LLC | 42858-0150-14 |
| Scopolamine Transdermal System | SCOPOLAMINE 1 mg/1 | Patch, Extended Release · Transdermal | Padagis Israel Pharmaceuticals Ltd | 45802-0580-01 |
| Scopolamine | SCOPOLAMINE 1.5 mg/1 | Patch, Extended Release · Transdermal | Ingenus Pharmaceuticals, LLC | 50742-0505-04 |
| Scopolamine Trandermal System | SCOPOLAMINE 1 mg/1 | Patch, Extended Release · Transdermal | Bryant Ranch Prepack | 63629-8450-01 |
| Scopolamine | SCOPOLAMINE 1 mg/3d | Patch, Extended Release · Transdermal | Amneal Pharmaceuticals NY LLC | 69238-1662-02 |
| Scopolamine | SCOPOLAMINE 1 mg/3d | Patch, Extended Release · Transdermal | Zydus Pharmaceuticals USA Inc. | 70710-1846-02 |
| Scopolamine | SCOPOLAMINE 1 mg/3d | Patch, Extended Release · Transdermal | Bryant Ranch Prepack | 71335-3013-01 |
Alternative dosage forms of Scopolamine
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 21 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Scopolamine 1 mg/3d | Mylan | 24 patches | $4.335 | AB | Availability likely |
| scopolamine 1 mg/3d | Actavis | 4 patches | $4.335 | AB | Availability likely |
| Scopolamine 1 mg/3d | Rhodes | 10 patches | $4.335 | AB | Availability likely |
| Scopolamine Transdermal System 1 mg | Padagis | 1 patch | $4.335 | AB | Availability likely |
| Scopolamine 1.5 mg | Ingenus | 1 patch | $4.335 | AB | Availability likely |
| Scopolamine 1 mg/3d | Amneal | 10 patches | $4.335 | AB | Availability likely |
| Scopolamine 1 mg/3d | Zydus | 10 patches | $4.335 | AB | Availability likely |
| Transderm Scop 1 mg/3d | Baxter | 1 patch | — | AB | FDA listed |
| Scopolamine 1 mg/3d | A-S | 4 pouches | — | AB | FDA listed |
| scopolamine 1 mg/3d | A-S | 1 d | — | AB | FDA listed |
| Scopolamine Trandermal System 1 mg | Bryant | 1 patch | — | AB | FDA listed |
| Scopolamine Trandermal System 1 mg | Bryant | 1 patch | — | AB | FDA listed |
| Scopolamine Trandermal System 1 mg | Bryant | 1 patch | — | AB | FDA listed |
| Scopolamine 1.5 mg | NuCare | 1 patch | — | AB | FDA listed |
| Scopolamine 1 mg/3d | Zydus | 10 patches | — | AB | FDA listed |
| Scopolamine Transdermal System 1 mg | Bryant | 1 patch | — | AB | FDA listed |
| Scopolamine 1 mg/3d | Bryant | 4 patches | — | AB | FDA listed |
| Scopolamine 1 mg/3d | Bryant | 10 patches | — | AB | FDA listed |
| Scopolamine 1 mg/3d | Bryant | 24 patches | — | AB | FDA listed |
| Scopolamine Trandermal System 1 mg | Bryant | 1 patch | — | AB | FDA listed |
| Scopolamine 1 mg/3d | Bryant | 4 patches | — | AB | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Scopolamine Transdermal System — that fall in the same broad treatment class (antiemetic/antivertigo agents) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Scopolamine Transdermal System shortage FAQs
Is Scopolamine Transdermal System in shortage?
Which products are affected?
When will Scopolamine Transdermal System be available again?
Can I still get Scopolamine somewhere?
What should I do if I take Scopolamine Transdermal System?
Still have a question about the Scopolamine Transdermal System shortage?
Ask a pharmacist about this shortage →View Scopolamine Transdermal System on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.